JPH0244030B2 - - Google Patents
Info
- Publication number
- JPH0244030B2 JPH0244030B2 JP57095572A JP9557282A JPH0244030B2 JP H0244030 B2 JPH0244030 B2 JP H0244030B2 JP 57095572 A JP57095572 A JP 57095572A JP 9557282 A JP9557282 A JP 9557282A JP H0244030 B2 JPH0244030 B2 JP H0244030B2
- Authority
- JP
- Japan
- Prior art keywords
- cea
- antibody
- antibodies
- segment
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 25
- 239000011159 matrix material Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 124
- 239000003795 chemical substances by application Substances 0.000 description 61
- 239000000203 mixture Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000012491 analyte Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000700 radioactive tracer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 102000012404 Orosomucoid Human genes 0.000 description 2
- 108010061952 Orosomucoid Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex⢠Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 1
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã®èæ¯
CEAã¯çé»ç¹PH4.5ãçæ°Žåç©å«éçŽ40ãªãã
75ééïŒ ãé«ãâã¢ã»ãã«ã°ã«ã³ãµãã³å«é
ïŒ10ãªãã30ééïŒ ïŒã埮éã®ïŒ®âã¢ã»ãã«ã¬ã©ã¯
ããµãã³ãããã³ïŒãªãã20ééïŒ ã®ã·ã€ã«é žã
æããç±å®å®æ§ç³ã¿ã³ãã¯è³ªã§ãããããã¯å ¬ç¥
æ¹æ³ã«ãã€ãŠè «çãŸãã¯çµç¹å¹é€ãã補é ãã
ããäžæããè¡æž CEAæ¿åºŠã¯ããçš®ã®ãããç¹
ã«èè žç®¡ã®ãããã«é¢é£ããŠããã®ã§ãCEAã¯
æ矩深ããCEAãã¬ãŒãµãŒïŒæšèããCEAé¡çž
äœïŒãCEAæäœããã³æšèããCEAæäœã¯ãã¹ãŠ
æ¢ç¥ã§ããïŒç±³åœç¹èš±ç¬¬3927193å·ããã³ç¬¬
3663684å·ïŒã α1é žæ§ç³ã¿ã³ãã¯è³ªãŸãã¯ãªããœã ã³ã€ã
ïŒä»¥åŸAGãšããïŒã¯ç±å®å®æ§ã§ããããŠçæ°Žå
ç©çŽ40ãªãã45ééïŒ ãã·ã€ã«é žããã³ã¢ã¹ãã©
ã®ã³é žçŽ10ééïŒ ããããŠCEAãšäŒŒãæ¿åºŠã§ã°
ã«ã¿ãã³é žãã¡ããªãã³ãâã¢ã»ãã«ã°ã«ã³ãµ
ãã³ããã³ïŒ®âã¢ã»ãã«ã¬ã©ã¯ããµãã³ãå«æã
ããAGã¯çé»ç¹PH2.7ãβâã°ãããªã³æå床ã§
ã¯ãªãαâã°ãããªã³é»æ°æ³³åæå床ãCEAã®
çŽ200000ã§ã¯ãªããŠçŽ45000ã®ååéãæããã
ãšã«ãããŠCEAãšå®è³ªçã«çžéãããäžæº¶æ§AG
ã¯å è¡æè¡ã«æ¢ç¥ã§ãããå ç«åŠçã«CEAãšäº€
å·®åå¿ããçš®ã ã®æ£åžžçµç¹äžã«ååšããç©è³ªïŒé
ç¹ç°æ§äº€å·®åå¿æåãŸãã¯NCAïŒã¯ç¥ãããŠã
ããããããç©è³ªã¯AGå ç«æ±ºå®å åãæããã
ã®ãšããŠåå®ãããŠããªãã æ¬çºæã®äžã€ã®ç®çã¯æ¢ç¥CEAã¢ãã»ã€ã®æ
床ãæ¹è¯ãããããŠãã®ç®çã®ããã®æ°èŠãªè©Šè¬
ãæäŸããããšã§ããã æ¬çºæã®ä»ã®äžç®çã¯CEA枬å®ã®ããã®æ°èŠ
ãªæ¹æ³ããã³è©Šè¬ãæäŸããããšã§ããã ãããããã³ä»ã®ç®çã¯æ¬æ现æžãå šäœãšããŠ
èæ ®ããããšã«ããèªæã§ãããã æ¬çºæã®æŠèŠ é©ãã¹ãããšã«ããããŠäºæãããããšã«ã
CEAååäžã«ã¯AGã«å¯Ÿãèããå ç«åŠççžäŒŒæ§
ãæããéšåãååšããããšãå€æããããã®çº
æã¯ä»¥äžã®æ°èŠãªæ¹æ³ããã³çµæç©ãžå°ããã ïŒ AGæäœãšäº€å·®åå¿ããªããCEAãã¬ãŒãµãŒ
ããã³æšæºã®äžéšåãé€ãããšã«ãã€ãŠã
CEAã¢ãã»ã€ã®æ床ãæ¹è¯ããããé€å»ã¯ã
亀差åå¿ããCEAãšãå容äœãšããŠAGæäœãš
ãçµåãããããŠCEAãååããããšã«ãã€
ãŠéæãããããã®CEAã¯ãåžçãããªã
CEAçµæç©ãããCEAæäœã«å¯ŸããŠé«ã芪å
æ§ã瀺ãã ïŒ CEAã¢ãã»ã€ã¯ãã»ã°ã¡ã³ããšAG決å®å
åã®äž¡æ¹ã瀺ãCEAã ãã枬å®ããæ°èŠãªæ¹
æ³ã«ãã€ãŠããã«æ¹è¯ããããæšèããAGã¯
æ°èŠã§ããããããŠæ¬çºæãèŠå®ããç¹èš±è«æ±
ã®ç¯å²ããã³ä»¥åŸã«èšèŒããããã®æ¹æ³ã«ãã
ãŠäœ¿çšãããã æ¬çºæã®è©³çŽ°ãªèª¬æ ãã®æ¹æ³ã«ãã€ãŠç²Ÿè£œãã¹ãCEA補å€ã¯ä»»æ
ã®æ £çšæ¹æ³ã«ãã€ãŠåŸãããšãã§ãããCEAã¯
æ®éçµç¹å¹é€ãŸãã¯è «çãäŸãã°èè žããã®è転
移ã®æœåºã«ãã€ãŠåŸããããCEAå«æåºçºç©è³ª
ã®å¥œé©ãªäžè£œé æ¹æ³ãç±³åœç¹èš±ç¬¬3663684å·ã«é
瀺ãããŠãããããããªãããã€ãšè€éã§ãªãæ¹
æ³ãæºè¶³ã§ããããäŸãã°ã现èãŸãã¯çµç¹è©Šæ
ã¯æ°Žäžã§ãã¢ãžããŒãããéå¡©çŽ é žã®ãããªç³ã¿
ã³ãã¯è³ªæº¶åªã§æœåºãïŒãŸãã¯ç±å€æ§ã¿ã³ãã¯è³ª
ãæ²æ®¿ããããã«70âã§å ç±ããïŒãäžæº¶ç©ãé€
å»ããããé å¿ããæ®äœã®éå¡©çŽ é žãéæãŸãã¯
éå¡©çŽ é žã«ãªãŠã æ²æ®¿æ³ïŒç±³åœç¹èš±ç¬¬4180556å·ïŒ
ã«ãã€ãŠé€å»ãããããŠCEAãååããããšã
ã§ããããã®CEAã¯å ¬ç¥ã®æ¹æ³ã§ã©ãžãªã¢ã€ãœ
ããŒããé µçŽ ãå®å®ãªããªãŒã©ãžã«ã«ãè£é µçŽ ã
è¢å åºãååŠã«ããã»ã³ã¹åºããŸãã¯é µçŽ é»å®³å€
ãããã¯è³ŠæŽ»å€ã®ãããªé©åœãªæ€åºå¯èœåºããã€
ãŠãåŸèšã®ç²Ÿè£œæäœã®ä»¥åãŸãã¯ä»¥åŸã«æšèãã
ããšãã§ããã ããã§ã®ç²Ÿè£œæ¹æ³ã®ç®çã¯ãAGæäœãšäº€å·®å
å¿æ§ã®CEAã«å¯ãããŸãã¯å®è³ªçã«è©²CEAãã
ãªã倩ç¶ãããã¯æšèCEAã調補ããããšã«ã
ããåžè²©ã®æŸå°æ§ãšãŒãåCEAã®ããªãã®éšå
ã¯AGæäœã«çµåããªããããŸãã¯éåžžã«åŒ±ãã
ãçµåããªããäŸãã°ããã®ãããªæŸå°æ§ãšãŒã
åCEA補å€ã®æŸå°èœã®çŽïŒåã®ïŒã ããAGæäœ
ãšçŽã¡ã«åå¿ããã«éãããä»æ¹è©²æŸå°èœã®çŽ50
ïŒ ä»¥äžã¯äžå€ã€ã³ããŠããŒã·ãšã³åŸã«ããããçµ
åããã§ããããCEA補å€ã®éçµåéšåã®æ¬äœ
ã¯çŸåšæªç¥ã§ãããããã¯å€Ÿéã¿ã³ãã¯ãå«æã
ãã§ãããã CEA補å€ã®äžéšã¯AGæäœãçµåãåŸããã
CEAæäœã¯AGãçµåãåŸãªãããšã¯èå³ããäº
é ã§ããããã®ãã©ããã¯ã¹ã¯CEAæäœãã€ã
ãããæ¹æ³ã®ããã§ãããšä¿¡ãããããCEAæ
äœã¯æ £äŸçã«åç©ãCEA補å€ã§å ç«åããŠèª¿è£œ
ããããã®ããCEAã®AG決å®å åãšã該CEA補
å€äžã®ä»ã®CEA決å®å åããã³å€Ÿéç©ãšã®äž¡æ¹
ã«ç¹ç°æ§ã®æäœã®çºçãžã¿ã¡ã³ãã次ã«å ç«ãã
CEA補å€äžã®å€Ÿéç©ã«å¯ŸããŠäžæãããéCEA
æäœãé€å»ããæå³ã§ãæè¡æž ãæ£åžžãªçµç¹ãšã€
ã³ããŠãŒããŒãããããããããªããCEAã«å¯Ÿ
ããŠäžæãããæäœéå£ã¯æ£åžžçµç¹æåã§ãã
AGã«ç¹ç°çãªæäœããå«ãããã®ããã«AGæ
äœã¯æ£åžžçµç¹ãšã®ã€ã³ããŠãŒãã·ãšã³ã«ãã€ãŠé€
å»ããããæ®ãã®CEAæäœã¯åŸã€ãŠAGæäœãšäº€
å·®åå¿æ§ã§ãªããããªãã¡AGã®ãããã«é¡äŒŒã®
å ç«éšäœãæããªãCEAã®éšåã«åããããã
ãã§ããã以åŸãã®éšåãCEA ã»ã°ã¡ã³ããš
åŒã¶ããã®ã»ã°ã¡ã³ãã«ç¹ç°æ§ã®æäœã¯CEA 
ã»ã°ã¡ã³ãæäœã§ãããã»ã°ã¡ã³ããšAGå ç«
éšäœã®äž¡æ¹ãå«æããCEAãã以åŸäŸ¿å®äžç¡å·
ã®CEAãšåŒã¶ã ç¡å·ã®CEAã粟補ããããã®å¥œãŸããæ¹æ³ã¯ã
äžçŽåºçºçµæç©ãAGæäœããã€ãŠåžçããåºçº
çµæç©ã®æªçµåæ®éšãé€å»ãããããŠCEAãAG
æäœããåé¢ããããšã䌎ããäžçŽçµæç©äžã«å
åšããããç¥ããªãAGããCEAãæåã«åé¢ã
ãå¿ èŠã¯ãªããAGã®AGæäœã«å¯Ÿãã芪åæ§ã¯
ç¡å·ã®CEAã®ãããããèããé«ãããã®ããã
AGæäœãžçµåããAGãéé¢ããAGæäœçµå
CEAã®æº¶é¢ã®ããã®æ¡ä»¶ã®æ³šææ·±ãéžæããã³
å¶åŸ¡ã¯ãäºã€ã®ç©è³ªã®AGæäœã«å¯Ÿãã芪ååã®
å·®ã«åºã¥ããŠCEAãAGããåé¢ããããšãå¯èœ
ã«ããã§ãããã ãã€ãŠç²Ÿå·§ãªæäœã¯ãäžçŽCEAå«æçµæç©ã
CEA ã»ã°ã¡ã³ãã ããçµåãåŸãæäœãšæ¥è§Š
ãããçµåç©è³ªãçµæç©æ®éšããåé¢ããæäœã«
ããåžçãããCEAãåé¢ããŠäžéçµæç©ãç
æãããäžéçµæç©äžã®ç¡å·ã®CEAãAGæäœãž
çµåãããçµåããç¡å·ã®CEAãæ®éšããåé¢
ãããããŠç¡å·ã®CEAãAGæäœããåé¢ããã
ãšãå«ãã çµåCEAãæããæäœãæªçµåç©è³ªã®æ®éšã
ãåé¢ããããšãå«ãåè¿°ã®ã¹ãããã¯ãæäœã
溶液ããåé¢ããããã®ä»»æã®æ¢ç¥æ¹æ³ã«ãã€ãŠ
éæããããšãã§ããããã®ãããªæ¹æ³ã¯ãæ®é
æäœãäžæº¶åããããšã䌎ããããã¯æäœã
CEAãžçµåããåããåŸã®ãããã§ãå®æœãã
ããšãã§ããã 奜ãŸããã¯ã該æäœã¯CEAãšæ¥è§Šãããåã«
æ°Žäžæº¶æ§åããããããã¯æäœãæ°Žäžæº¶æ§æ äœãž
å ±æçµåãããïŒBiou et alïŒâChin.Biochen.â
ãOttawaã10ãïŒãïŒ141âïŒã1977ãïŒããŸãã¯æ
äœãéå ±æçµåçã«é©åœãªæ äœãžåžçãã
ïŒWang et alïŒâClin.Chem.â25ãïŒãïŒ546âïŒ
ã1979ãïŒããšã«ãã€ãŠéæãåŸãã代衚çãªæ äœ
ã«ã¯æ¶æ©ããã¹ãã©ã³ã®ãããªããªãªãŒã«ãã»ã«
ããŒã¹ãã¬ã©ã¹ãŸãã¯ãã€ãã³ãå«ããæ äœã¯ç¹
ç¶ç¶å¡ãããŒãºãŸãã¯é¡ç²ã®åœ¢ã§ãããæ äœãæ
äœãžå ±æçµåã«ãã€ãŠçµåããããšããã¢ããã
ãšãŒãã«ãŸãã¯ãšã¹ãã«ã®ãããªææ©çµååºãæ
äœãæ äœãžå ±æçµåããããã«çšãããããæäœ
ãäžæº¶åããããã®é©åœãªææ³ã¯åœæ¥è ã«ãã€ãŠ
容æã«éžæããããããŠæ¬çºæã«ãšã€ãŠéèŠã§ãª
ãã AGæäœããã³CEA ã»ã°ã¡ã³ãæäœã¯åžè²©
ãããŠããããŸãã¯ãããã¯æ¢ç¥æ¹æ³ã§èª¿è£œãã
ããšãã§ãããAGæäœã¯ã¢ãžãŠãã³ãäžã®AG
溶液ã«ããå ç«åããããšã«ããããŠãµã®ãŸãã¯
ã€ã®ã®ãããªå®éšåç©äžã«å®¹æã«ã€ããããã CEA ã»ã°ã¡ã³ãæäœã¯åè¿°ã®ããã«CEAã
調補ããå®éšåç©ãå ç«åãããããŠCEAãšå
ãèµ·æºããã®æ£åžžçµç¹ã§æè¡æž ãåžçããããšã«
ãã€ãŠè£œé ãããããã®æåŸã®å·¥çšã¯äžè¬ã«æ £çš
ã§ããããããŠããã¯AGæäœãé€å»ããããã©
ãããã®ç®çãšããŠåç©ãå ç«åããããã«äœ¿çš
ããCEA補å€äžã«ååšãåŸãæ£åžžãªéCEA借é
ç©ã«å¯Ÿããæäœã®é€å»ãå«ããå ç«åããåç©ã
ãã®æè¡æž ã¯ãã®ãŸã䜿çšããŠãããããŸãã¯æ¢
ç¥ã®æ æ§ãäŸãã°ã¯ãããã°ã©ãã€ãŒãé»æ°æ³³
åãããã³ææã®é¡äŒŒæ¹æ³ã§ããã«ç²Ÿè£œããããš
ãã§ããã å žåçã«ã¯ãç¡å·ã®CEAã¯æäœãèåã·ã¢ã³
掻æ§åæ¶æ©ããã¹ãã©ã³ãžçµåããããšã«ããã
æšèããããŸãã¯å€©ç¶ããªãã¡æšèããªãCEA
補å€ããååããããäžæº¶æ§æäœã¯ã«ã©ã ã«å å¡«
ããããããŠäžæ§PHè¿ãã§ç·©è¡æ¶²ã§å¹³è¡¡åãã
ããæšèãããããŸãã¯å€©ç¶CEAã¯ã«ã©ã äžã®
éç¹ç°æ§çµåãæžããã®ãå©ãããããæ£åžžè¡æž
ãšæ··åãããã次ã«CEAçµæç©ãé垞宀枩ã§ã«
ã©ã ãžå ãããããçµæç©ãæäœãšæ¥è§Šãä¿ã€ãŠ
ããæéã¯æ°åïŒééæéïŒããçŽ24æéãŸã§å€
åããã§ããããçŽ10æéãäžè¬ã«å¥œãŸãããã€
ã³ããŠããŒã·ãšã³æéãé·ããã°é·ãçšãããå€
éã®CEAååãåŸãã§ãããããæéã¯éèŠã§
ãªãã ã€ã³ããŠãŒãã·ãšã³ãçµäºããåŸãæ®ãã®æªçµ
ååç»ã¯äžæ§è¿ãã«ä¿ã€ãç·©è¡æ¶²ã§æº¶é¢ãããã
次ã«çµåããåç»ãéé¢å€ã§æº¶é¢ããããæåâ
æäœè€åäœãåé¢ãããä»»æã®ç©è³ªãŸãã¯æ¡ä»¶ã
éé¢å€ãšããŠäœ¿çšãåŸããé žã®ã»ãã®äŸã¯ãå°¿çŽ
ããã³å¡©é¡ãå«ãã溶é¢å·¥çšã¯CEA溶é¢ãæ倧
ã«ããªãããAG溶é¢ãæå°ã«ããããã«æé©å
ãããããã®ããšã念é ã«çœ®ããåœæ¥è ã¯åºçºçµ
æç©ã®æ¬è³ªãäžæº¶æ§æäœãææã®ç²Ÿè£œåºŠãCEA
ãæšèåãããŠãããã©ããããããããªãæšè
ã®æ¬è³ªã«äŸåããŠæº¶é¢æ¡ä»¶ã調ç¯ããé©åœãªæº¶é¢
液ãéžæããã§ãããã ååãããç¡å·ã®ãæšèãŸãã¯å€©ç¶CEAã¯ã
ããæããªãã°æ®ãã®AGãé€å»ããããããã«
粟補ãããããŠäœ¿çšãããŸã§åçµä¹Ÿç¥ãããã¯å·
åä¿åããããšãã§ããã粟補ããç¡å·ã®CEA
ã¯ãããŸã§CEAã«é©ããã©ããªçšéã«ããäŸã
ã°æ¢ç¥ã®CEAã¢ãã»ã€ã«ãããŠãã¬ãŒãµãŒïŒæš
èããé¡çžäœïŒãšããŠããŸãã¯CEAæäœè£œé ã®
ããã®å ç«æºãšããŠäŸããããšãã§ãããäžèšã®
ããã«èª¿è£œãã粟補CEAãã¬ãŒãµãŒã®äœ¿çšã¯ã
æ¢ç¥ã¢ãã»ã€ã§å®è¡ãããŠãããããªè©Šæã®éå¡©
çŽ é žãããã¯ç±æœåºãçç¥ã§ãããããŠè¡æž ã®ã
ããªæªåŠçè©ŠæãçŽæ¥äœ¿çšã§ããã®ã§ãã€ã ãã¢
ãã»ã€ã®æ床ãå¢ãã ã€ã ãã¢ãã»ã€ äžã§èª¿è£œããã粟補ããæšèããCEAãå žå
çãªç«¶ååã€ã ãã¢ãã»ã€ã«äœ¿çšããããšã¯æ¬çº
æã®ç¯å²å ã§ããããã®ããšã¯ãæšèããCEA
ãšãã¹ãè©Šæãšãéãããæ°ã®CEAæäœçµåéš
äœã«å¯ŸããŠç«¶åãããã®åŸæäœçµåç©è³ªãæšèã«
ã€ããŠå®éããããããå€éã®è©ŠæCEAãååš
ããã°ããã®ãšãã¯æšèããCEAã®å€§éšåã¯ç«¶
åçã«æäœãã眮æããããè©Šæäžã®CEAãäœ
ããã°ãã®å察ã§ãããAGæäœã«ãã€ãŠçµåã
ããªãã¿ã³ãã¯è³ªãå®è³ªäžå«ãŸãªãæšèãã
CEAãããªãã¡ããã®ããã«çµåãããªãã¿ã³
ãã¯è³ªãçŽ40ïŒ ä»¥äžããå«ãŸãªãæšèããCEA
ã«ããããããã³ãã©ããã·ãŠããã³CISãã販
売ãããŠããåžè²©ã®ã©ãžãªã€ã ãã¢ãã»ã€ã«ããª
ãã®æ¹åãåŸãããšãã§ããã粟補ããæšè
CEAã¯æªç²Ÿè£œãã¬ãŒãµãŒãããCEAæäœã«å¯Ÿã
ãŠèããå ç«åå¿æ§ã§ãããåé¡ã¯ããããŸã§
CEAã¯å€§éšååäžã§ãããšèããããŠãããã
å®éã«ã¯ç¡å·ã®CEAäžã«AGããã³ïŒ°ã»ã°ã¡ã³ã
決å®éšåãååšãããã¹ãè©ŠæCEAã®æªç¥å²å
ã ããã»ã°ã¡ã³ã決å®éšåã§ãããšããããšã§
ãããè©Šæã»ã°ã¡ã³ãã¯åŸæ¥ã®ç«¶ååã€ã ãã¢
ãã»ã€ã«ãããŠæšèããã³è©Šæã®ç¡å·ã®CEAãš
競åããããã«ããç¡å·ã®CEAã®å®éã劚害ã
ããã®ãšæšæž¬ãããããã®æœåšçãªåŠšå®³ã¯ããã®
ç¹ãèæ ®ã«å ¥ããã¢ãã»ã€ãããã³ãŒã«ãéžã¶ã
ãšã«ãã€ãŠæé€ããããåŸã€ãŠãæ¬çºæã®æ¹è¯ã¯
ç¡å·ã®CEAã®ã¿ãããªãã¡AGããã³ïŒ°ã»ã°ã¡ã³
ãã«å ±éãªå ç«åŠçã«è¡šããã決å®å åãå«æã
ãç©è³ªã®ã¿ã枬å®ããããšãå«ããããã¯éAG
æäœäº€å·®åå¿æ§ç©è³ªããã¹ãè©Šæããäºå粟補ã«
ãã€ãŠé€å»ãã次ã«è©Šæã競åç³»ã«ãã€ãŠå®éã
ãããšã«ãã€ãŠéæããããšãã§ãããããããª
ããã奜é©ãªå®éæ³ã¯æ¬çºæã«ãã€ãŠã¯æ¹è¯ãã
ãµã³ãã€ããæ³ã§ããã ãµã³ãã€ããã€ã ãã¢ãã»ã€æ³ã¯ããç¥ãããŠ
ãããäžè¬çã«ããã®ã¢ãã»ã€ã«äœ¿çšãããè©Šè¬
ã¯è¢«åæç©è³ªã«å¯Ÿããäžæº¶æ§æäœãšã被åæç©è³ª
ã«å¯Ÿããæšèããå¯æº¶æ§æäœãšã§ãããäºæãã
ãè©Šæ被åæç©è³ªéå£ãããå°æ°ã®è¢«åæç©è³ªçµ
åéšäœãå«æããéã®äžæº¶æ§æäœã䜿çšãããã
ãã®ã¢ãã»ã€ã¯äžè¬ã«äžæº¶æ§æäœããã¹ãè©Šæã
次ã«æšèããæäœãšé çªã«æ¥è§Šãããçµåããæš
èãã¢ãã»ã€ããããšã«ãã€ãŠå®æœãããã被å
æç©è³ªã¯äžæº¶æ§æäœãšæšèæäœãšã®éã«ãµã³ãã€
ããããããããã«ã¯å¿è«è¢«åæç©è³ªãå°ãªããš
ãäºã€ã®å ç«çµåéšäœãæã€ãŠããããšãèŠã
ããç¡å·ã®CEAã®ã¢ãã»ã€äžã®CEA ã»ã°ã¡ã³
ãã®ååšã®å¯èœæ§ã¯ãã®ã¢ãã»ã€ã®äžã€ã®å€æ³ã
奜ãŸãããã®ãšãããå¯æº¶æ§ã®æšèããæäœãšäž
溶æ§æäœãšã¯ãå ±ã«åã被åæç©è³ªãšçµåããã
ãã©ãåãæäœã§ã¯ãªããããªãã¡äžæ¹ã®æäœã¯
ç¡å·ã®CEAã®ïŒ°ã»ã°ã¡ã³ã決å®å åã«åãã第
äºã®æäœã¯CEA AG決å®å åãçµåããããšã
ã§ãããããã¯AGãŸãã¯ïŒ°ã»ã°ã¡ã³ãã®ã©ã¡ã
ããç¡å·ã®CEAã®æš¡å£ãããããšãé²æ¢ããã ãã®æ¹è¯ãããµã³ãã€ããæ³ã¯ã (a) ãã¹ãè©ŠæãCEAã®ïŒ°ã»ã°ã¡ã³ãã«å¯Ÿãã
æ°Žäžæº¶æ§æäœãå«ããã¹ããããªãã¯ã¹ãšæ¥è§Š
ãããããšã (b) ãã¹ãè©Šæã®æ®ããé€å»ããããšã (c) ãã¹ããããªãã¯ã¹ãAGã«å¯Ÿããæšèãã
æäœãšæ¥è§Šãããããšã (d) çµåããªãæšèããæäœãé€å»ããããšã (e) çµåãŸãã¯æªçµåæšèã®éã枬å®ããããš ãå«ãã äŸç€ºã®ããããã®æ¹æ³ã®æçµçæç©ã¯ä»¥äžã®ã
ãã«ãªãã§ãããã ãè¡šã äžèšã«ãããŠç¹ç·ã¯å ç«çµåã§ãããâ»ã¯æšè
ã§ããã çµåããCEA ã»ã°ã¡ã³ãã¯æšèããæäœã«
ãã€ãŠçµåããããåŸã€ãŠCEAãšããŠå®éãã
ãªããååšããããšãããCEA ã»ã°ã¡ã³ãã¯
AGæäœãçµåããªããïŒãŸãã¯ãã以äžã®å¥ã
ã®å ç«éšäœãçµåããããšãã§ããåçš®ã®æäœã
䜿çšããããšãã§ãããå¿è«ïŒ°ã»ã°ã¡ã³ãæäœã¯
AGãšäº€å·®åå¿æ§ã§ãã€ãŠã¯ãªããããŸãAGæ
äœã¯CEA ã»ã°ã¡ã³ããçµåããŠã¯ãªããªãã
ããã«ãããããããæäœã¯ããããã§ããã ã
åäžã§ããããšãæãŸãããããªãã¡æ¢ç¥ææ³ã§
ãã€ããªããŒãå¹é€ã«ãã€ãŠåŸãããšãã§ããã
ããªãåäžã®å ç«éšäœã«åããããåäžã®æäœã
䜿çšãã¹ãã§ããã ã»ã°ã¡ã³ãæäœã¯ãAGæäœãå ã«è£œé ãã
ãæ¹æ³ãšåãæ¹æ³ã§äžæº¶æ§åããããšãã§ããã
奜ãŸããã¯ãæäœã¯ãããããªã¹ãã¬ã³ããŒãºãŸ
ãã¯ããªãããã¬ã³è©Šéšç®¡å åºãžåžçãããããš
ã«ãã€ãŠäžæº¶æ§åãããã æšèããæAGæäœã¯æ°èŠã§ãããšæãããã
åè¿°ã®CEAã«å¯Ÿããæšèã®ã©ãããAGæäœã«ã
䜿çšã§ããä»ã®æšèããæäœãšåãæ¹æ³ã§è£œé ã
ãããäŸãã°ãæŸå°æšèããæCEAæäœã®è£œé
æ³ãèšèŒããç±³åœç¹èš±ç¬¬3927193å·åç §ã奜ãŸã
ãæšèã¯é µçŽ ããã³ã©ãžãªã¢ã€ãœããŒãã§ããã
æã奜ãŸããã®ã¯æŸå°æ§ãšãŒãã§ãããæŸå°æ§ãš
ãŒãåã®ããã®å¥œãŸããæ¹æ³ã¯ãDermody et
al.ïŒâClinical Chemistryâ25(6)ïŒ989â995
ïŒ1979ïŒãŸãã¯Parsons et al.ïŒâAnalytical
Biochemistryâ95ïŒ568â574ïŒ1979ïŒã«èšèŒãã
ãŠããããã«ã¯ãã©ãã³âãŸãã¯ã©ã¯ããã«ãª
ãã·ããŒãŒãïŒ 125IïŒãšãŒãããããã·ããšãã«
ããããªããŒãââããããã·ã¹ã¯ã·ãã¡ãŒã
ãšã¹ãã«ïŒBolton et al.ïŒâBiochem.Journalâ
133ïŒ529â533ã1973ãïŒãïŒ 125IïŒãžãšãŒããã«ãª
ã¬ã»ã€ã³ã€ãœããªã·ã¢ããŒãïŒGabel et al.ïŒ
âAnalytical Biochemistryâ86ïŒ396â406
ã1973ãïŒãïœâãããã·ã«ã«ããã«ââïŒ125IïŒ
ãšãŒãããã·ã³ââããããã·ã¹ã¯ã·ããããš
ã¹ãã«ïŒAssoian et al.ïŒâAnalytical
Biochemistryâ103ïŒ70â76ã1980ãïŒããŸãã¯IC1
ïŒMontelaro et al.ïŒâAnalytical
Biochemistryâ99ïŒ92â96ã1979ãïŒã®ãããªå€
éšæŸå°æ§ãšãŒãåå°ååã䜿çšãããã¯ãã©ãã³
æ³ã奜ãŸããå ·äœäŸã§ããã æ¬çºæã¯ä»¥äžã®å®æœäŸã«ããã«è©³ããèšèŒãã
ãã å®æœäŸ ïŒïŒåèäŸïŒ AGæäœïŒããã¹ããŸãã¯ãã€ã«ã¹ïŒããã®æ
å³ããå®æœäŸããã³Greenwood et al.ïŒ
âBiochem.J.â89ïŒ114â123ïŒ1963ïŒã®æ¹æ³ã«ã
ã€ãŠ 125Iã§æšèãããæäœã®50ÎŒïœéšåæšæ¬ã
Greenwoodãã®æ¹æ³ã§åŠçããã»ãã¢ããã¯ã¹
â50ã®ã«ã©ã ãééãããããšã«ãã€ãŠéé¢ãš
ãŒããåé¢ãããæšèããæäœåç»ã¯ãïŒïŒ åãŠ
ã·è¡æž ããã³æèå€ãšããŠ0.1ïŒ NaN3ãå«ãåžé
液äžã«çŽ3ÎŒCiïŒmlã«åžéãããã補åã¯ïŒâã§
貯èµããã å®æœäŸ ïŒ ãã®æ¹æ³ã¯ç¡å·ã®CEAã枬å®ããããã®äŒå³
ãããæ¹è¯ãµã³ãã€ããã€ã ãã¢ãã»ã€ãèšèŒã
ãã CEAã¯çµè žã®äžæ¬¡ã¢ããã«ã«ãããŒãã®è転
移ããã該çµç¹ã®Warringãã¬ã³ããŒäžçéã®èž
çæ°Žäžã«ãã¢ãžãã€ãºããããšã«ãã€ãŠç²Ÿè£œãã
ãããã¢ãžããŒãã¯8000rpmã«ãããŠ30åéïŒâ
ã§é å¿ããããšã«ããæž æŸåããããäžæž ã1M
éå¡©çŽ é žãšæ··åããæ²æ®¿ãé å¿ã«ãã€ãŠé€å»ã
ããäžæž ãèžçæ°Žã§ïŒæ¥ééæããã ã¿ã³ãã¯è³ª50mgïŒmlãå«ãã§ããéå¡©çŽ é žæœåº
åç»ãPH7.8ã®0.05Mãªã³é žç·©è¡æ¶²ã§å¹³è¡¡åãã
ã»ãã¢ããã¯ã¹ïŒ§â200ã«ã©ã ïŒ170Ã1.5cmïŒã§
ã²ã«ãéããããšã«ãã€ãŠç²Ÿè£œããã溶åºæ¶²ãïŒ
mlã¥ã€ã®éšåæšæ¬ãšããŠéããã¿ã³ãã¯è³ªã
280nmã«ãããŠããããŠCEAãã©ãžãªã€ã ãã¢
ãã»ã€ã§ã¢ãã¿ãŒããã溶åºæ¶²ã®æåã®ã¿ã³ãã¯
質ããŒã¯ïŒç©ºéäœç©ïŒãéããŠæ¿çž®ãã次ã«ã²ã«
ãéãããè¿ããã CEA ã»ã°ã¡ã³ãæäœã¯ãäžèšCEA補å€ã®ïŒ
mgãå®å šãªããã€ã³ãã¢ãžãŠãã³ãäžã«ä¹³åãã
ãšãã«ãžãšã³ããŠãµã®ã«æ³šå°ããCEAã¿ã€ã¿ãŒ
ãäžæããåŸã«è¡æž 20mlãæ¡åãããããŠæè¡æž
ãéããèèçµç¹ããã³æ£åžžããè¡æž ãžåžçãã
ãããšã«ãã€ãŠäœãããã補å€ã¯ïŒâã§è²¯èµã
ãã çŽïŒmlã®CEA ã»ã°ã¡ã³ãæè¡æž ãç±³åœç¹èš±
第3686346å·ã«ãã€ãŠããªãããã¬ã³è©Šè¬ç®¡ã®å
è¡šé¢ã®åºã«å¡åžãããè žã®ã¢ããã«ã«ãããŒãã
æããããšãæ¢ç¥ã®æ£è ã®è¡æž è©Šæ0.1mlãšãæ£
åžžã³ã³ãããŒã«0.1mlãšãïŒç³»åå¡åžè©Šéšç®¡äžã«
ãããããã12æéã€ã³ããŠããŒããããçµåã
ãªãè©Šæãæ°Žã§åè©Šéšç®¡ããæŽæµããå®æœäŸïŒã«
ãããŠèª¿è£œããæšèããAGæäœ0.3mlãåè©Šéšç®¡
ãžå ãã24æéã€ã³ããŠããŒãããçµåããªãæš
èæäœãæ°Žã§è©Šéšç®¡ããæŽæµãããããŠè©Šéšç®¡ãž
çµåããæŸå°èœã枬å®ãããè©Šæè©Šéšç®¡ãžçµåã
ãæŸå°èœã¯ã³ã³ãããŒã«äžã®ãããããèãã倧
ã§ãã€ãã å®æœäŸ ïŒïŒåèäŸïŒ ãã®å®æœäŸã¯æŸå°æ§ãšãŒãåCEA補å€ïŒãã
ãã³ãã©ããã·ãŠãïŒ1000000cpmïŒã®ç²Ÿè£œæ³ãèš
èŒãããAGã«å¯Ÿããäžæº¶æ§æäœã¯AGæäœïŒã¬
ã³ãã°ãããªã³âDakoïŒ300mgãèåã·ã¢ã³æŽ»æ§
åã»ãã¢ããŒãº4BïŒãã¢ã«ãã·ã¢ïŒ30mlãžçµåã
ãããšã«ãã€ãŠäœããããäžæº¶æ§æäœã¯ïŒÃ1.0
cmã®ã«ã©ã ã«å å¡«ãããã 125IæšèCEAã®éšå
æšæ¬ãæ£åžžãŠãµã®è¡æž ãšæ··åããåèšã«ã©ã ãžæ³š
ããPH7.8ã®0.05Mãªã³é žç·©è¡æ¶²ã§æº¶é¢ããïŒçª
ç®ã®éšåæšæ¬ã泚å ããçŽåŸïŒâã§äžå€ã€ã³ããŠ
ããŒãããæ£åžžãŠãµã®è¡æž 0.1mlãã«ã©ã ã«æ³šå
ãããããŠã«ã©ã ããªã³é žç·©è¡æ¶²ã§æº¶é¢ãããã
ããã®åç»ãæªçµååç»ãšåŒã¶ãçµååç»ã¯æªçµ
ååç»ãéããåŸãäž¡æ¹ã®å ŽåãšãPH2.2ã®0.1M
ã°ãªã·ã³ç·©è¡æŽã§æº¶é¢ãããååç»ã®æŸå°èœãã«
ãŠã³ããããè¡šïŒã¯ãã®çµæãèšé²ããã ãè¡šã ãã¬ãŒãµãŒã®å°éãã«ã©ã ã«æ®ãã®ã§ãçµåã
ãã³æªçµåæŸå°çã¯å šäœã§100ïŒ ã«éããªããå
æ§ãªçµæã¯ä»ã®ïŒäŸçµŠæºïŒããã¹ãããã³ãã€ã«
ã¹ã©ãã©ããªãŒãºïŒããã®AGæäœã䜿çšããæŸ
å°æ§ãšãŒãåCEAã®ããªãšãã¬ã³ã°ãªã³ãŒã«ä¿
é²æ²æ®¿æ³ã«ãã€ãŠåŸããããæ®ãã©ãã¹ãŠã®çµå
溶é¢æŸå°èœã¯AGæäœïŒDakoïŒã§ããCEAæäœ
ã§ãæ²æ®¿ãããããããæªçµååç»äžã«ã¯ã³ã³ã
ããŒã«ã«æ¯èŒããŠææãªæ²æ®¿æŸå°èœã¯çºèŠãããª
ãã€ããAGæäœãçµåããCEAã¯ã(1)AGã¯AG
æäœããã®CEAæŸå°èœãçšéåå¿çã«çœ®æãã
(2)ä»ã®è¡æž ã¿ã³ãã¯è³ªã«å¯Ÿããæè¡æž ã¯CEAã
æ²æ®¿ããªãããšããå ç«ç¹ç°æ§ã§ããããšã瀺ã
ããã çµåãã溶é¢åç»ã¯ãåžè²©CEA枬å®ããã
ïŒCISããã³ãããã³ãã©ããã·ãŠïŒã®æªç²Ÿè£œã
ã¬ãŒãµãŒã«ä»£ããŠçšããããã
75ééïŒ ãé«ãâã¢ã»ãã«ã°ã«ã³ãµãã³å«é
ïŒ10ãªãã30ééïŒ ïŒã埮éã®ïŒ®âã¢ã»ãã«ã¬ã©ã¯
ããµãã³ãããã³ïŒãªãã20ééïŒ ã®ã·ã€ã«é žã
æããç±å®å®æ§ç³ã¿ã³ãã¯è³ªã§ãããããã¯å ¬ç¥
æ¹æ³ã«ãã€ãŠè «çãŸãã¯çµç¹å¹é€ãã補é ãã
ããäžæããè¡æž CEAæ¿åºŠã¯ããçš®ã®ãããç¹
ã«èè žç®¡ã®ãããã«é¢é£ããŠããã®ã§ãCEAã¯
æ矩深ããCEAãã¬ãŒãµãŒïŒæšèããCEAé¡çž
äœïŒãCEAæäœããã³æšèããCEAæäœã¯ãã¹ãŠ
æ¢ç¥ã§ããïŒç±³åœç¹èš±ç¬¬3927193å·ããã³ç¬¬
3663684å·ïŒã α1é žæ§ç³ã¿ã³ãã¯è³ªãŸãã¯ãªããœã ã³ã€ã
ïŒä»¥åŸAGãšããïŒã¯ç±å®å®æ§ã§ããããŠçæ°Žå
ç©çŽ40ãªãã45ééïŒ ãã·ã€ã«é žããã³ã¢ã¹ãã©
ã®ã³é žçŽ10ééïŒ ããããŠCEAãšäŒŒãæ¿åºŠã§ã°
ã«ã¿ãã³é žãã¡ããªãã³ãâã¢ã»ãã«ã°ã«ã³ãµ
ãã³ããã³ïŒ®âã¢ã»ãã«ã¬ã©ã¯ããµãã³ãå«æã
ããAGã¯çé»ç¹PH2.7ãβâã°ãããªã³æå床ã§
ã¯ãªãαâã°ãããªã³é»æ°æ³³åæå床ãCEAã®
çŽ200000ã§ã¯ãªããŠçŽ45000ã®ååéãæããã
ãšã«ãããŠCEAãšå®è³ªçã«çžéãããäžæº¶æ§AG
ã¯å è¡æè¡ã«æ¢ç¥ã§ãããå ç«åŠçã«CEAãšäº€
å·®åå¿ããçš®ã ã®æ£åžžçµç¹äžã«ååšããç©è³ªïŒé
ç¹ç°æ§äº€å·®åå¿æåãŸãã¯NCAïŒã¯ç¥ãããŠã
ããããããç©è³ªã¯AGå ç«æ±ºå®å åãæããã
ã®ãšããŠåå®ãããŠããªãã æ¬çºæã®äžã€ã®ç®çã¯æ¢ç¥CEAã¢ãã»ã€ã®æ
床ãæ¹è¯ãããããŠãã®ç®çã®ããã®æ°èŠãªè©Šè¬
ãæäŸããããšã§ããã æ¬çºæã®ä»ã®äžç®çã¯CEA枬å®ã®ããã®æ°èŠ
ãªæ¹æ³ããã³è©Šè¬ãæäŸããããšã§ããã ãããããã³ä»ã®ç®çã¯æ¬æ现æžãå šäœãšããŠ
èæ ®ããããšã«ããèªæã§ãããã æ¬çºæã®æŠèŠ é©ãã¹ãããšã«ããããŠäºæãããããšã«ã
CEAååäžã«ã¯AGã«å¯Ÿãèããå ç«åŠççžäŒŒæ§
ãæããéšåãååšããããšãå€æããããã®çº
æã¯ä»¥äžã®æ°èŠãªæ¹æ³ããã³çµæç©ãžå°ããã ïŒ AGæäœãšäº€å·®åå¿ããªããCEAãã¬ãŒãµãŒ
ããã³æšæºã®äžéšåãé€ãããšã«ãã€ãŠã
CEAã¢ãã»ã€ã®æ床ãæ¹è¯ããããé€å»ã¯ã
亀差åå¿ããCEAãšãå容äœãšããŠAGæäœãš
ãçµåãããããŠCEAãååããããšã«ãã€
ãŠéæãããããã®CEAã¯ãåžçãããªã
CEAçµæç©ãããCEAæäœã«å¯ŸããŠé«ã芪å
æ§ã瀺ãã ïŒ CEAã¢ãã»ã€ã¯ãã»ã°ã¡ã³ããšAG決å®å
åã®äž¡æ¹ã瀺ãCEAã ãã枬å®ããæ°èŠãªæ¹
æ³ã«ãã€ãŠããã«æ¹è¯ããããæšèããAGã¯
æ°èŠã§ããããããŠæ¬çºæãèŠå®ããç¹èš±è«æ±
ã®ç¯å²ããã³ä»¥åŸã«èšèŒããããã®æ¹æ³ã«ãã
ãŠäœ¿çšãããã æ¬çºæã®è©³çŽ°ãªèª¬æ ãã®æ¹æ³ã«ãã€ãŠç²Ÿè£œãã¹ãCEA補å€ã¯ä»»æ
ã®æ £çšæ¹æ³ã«ãã€ãŠåŸãããšãã§ãããCEAã¯
æ®éçµç¹å¹é€ãŸãã¯è «çãäŸãã°èè žããã®è転
移ã®æœåºã«ãã€ãŠåŸããããCEAå«æåºçºç©è³ª
ã®å¥œé©ãªäžè£œé æ¹æ³ãç±³åœç¹èš±ç¬¬3663684å·ã«é
瀺ãããŠãããããããªãããã€ãšè€éã§ãªãæ¹
æ³ãæºè¶³ã§ããããäŸãã°ã现èãŸãã¯çµç¹è©Šæ
ã¯æ°Žäžã§ãã¢ãžããŒãããéå¡©çŽ é žã®ãããªç³ã¿
ã³ãã¯è³ªæº¶åªã§æœåºãïŒãŸãã¯ç±å€æ§ã¿ã³ãã¯è³ª
ãæ²æ®¿ããããã«70âã§å ç±ããïŒãäžæº¶ç©ãé€
å»ããããé å¿ããæ®äœã®éå¡©çŽ é žãéæãŸãã¯
éå¡©çŽ é žã«ãªãŠã æ²æ®¿æ³ïŒç±³åœç¹èš±ç¬¬4180556å·ïŒ
ã«ãã€ãŠé€å»ãããããŠCEAãååããããšã
ã§ããããã®CEAã¯å ¬ç¥ã®æ¹æ³ã§ã©ãžãªã¢ã€ãœ
ããŒããé µçŽ ãå®å®ãªããªãŒã©ãžã«ã«ãè£é µçŽ ã
è¢å åºãååŠã«ããã»ã³ã¹åºããŸãã¯é µçŽ é»å®³å€
ãããã¯è³ŠæŽ»å€ã®ãããªé©åœãªæ€åºå¯èœåºããã€
ãŠãåŸèšã®ç²Ÿè£œæäœã®ä»¥åãŸãã¯ä»¥åŸã«æšèãã
ããšãã§ããã ããã§ã®ç²Ÿè£œæ¹æ³ã®ç®çã¯ãAGæäœãšäº€å·®å
å¿æ§ã®CEAã«å¯ãããŸãã¯å®è³ªçã«è©²CEAãã
ãªã倩ç¶ãããã¯æšèCEAã調補ããããšã«ã
ããåžè²©ã®æŸå°æ§ãšãŒãåCEAã®ããªãã®éšå
ã¯AGæäœã«çµåããªããããŸãã¯éåžžã«åŒ±ãã
ãçµåããªããäŸãã°ããã®ãããªæŸå°æ§ãšãŒã
åCEA補å€ã®æŸå°èœã®çŽïŒåã®ïŒã ããAGæäœ
ãšçŽã¡ã«åå¿ããã«éãããä»æ¹è©²æŸå°èœã®çŽ50
ïŒ ä»¥äžã¯äžå€ã€ã³ããŠããŒã·ãšã³åŸã«ããããçµ
åããã§ããããCEA補å€ã®éçµåéšåã®æ¬äœ
ã¯çŸåšæªç¥ã§ãããããã¯å€Ÿéã¿ã³ãã¯ãå«æã
ãã§ãããã CEA補å€ã®äžéšã¯AGæäœãçµåãåŸããã
CEAæäœã¯AGãçµåãåŸãªãããšã¯èå³ããäº
é ã§ããããã®ãã©ããã¯ã¹ã¯CEAæäœãã€ã
ãããæ¹æ³ã®ããã§ãããšä¿¡ãããããCEAæ
äœã¯æ £äŸçã«åç©ãCEA補å€ã§å ç«åããŠèª¿è£œ
ããããã®ããCEAã®AG決å®å åãšã該CEA補
å€äžã®ä»ã®CEA決å®å åããã³å€Ÿéç©ãšã®äž¡æ¹
ã«ç¹ç°æ§ã®æäœã®çºçãžã¿ã¡ã³ãã次ã«å ç«ãã
CEA補å€äžã®å€Ÿéç©ã«å¯ŸããŠäžæãããéCEA
æäœãé€å»ããæå³ã§ãæè¡æž ãæ£åžžãªçµç¹ãšã€
ã³ããŠãŒããŒãããããããããªããCEAã«å¯Ÿ
ããŠäžæãããæäœéå£ã¯æ£åžžçµç¹æåã§ãã
AGã«ç¹ç°çãªæäœããå«ãããã®ããã«AGæ
äœã¯æ£åžžçµç¹ãšã®ã€ã³ããŠãŒãã·ãšã³ã«ãã€ãŠé€
å»ããããæ®ãã®CEAæäœã¯åŸã€ãŠAGæäœãšäº€
å·®åå¿æ§ã§ãªããããªãã¡AGã®ãããã«é¡äŒŒã®
å ç«éšäœãæããªãCEAã®éšåã«åããããã
ãã§ããã以åŸãã®éšåãCEA ã»ã°ã¡ã³ããš
åŒã¶ããã®ã»ã°ã¡ã³ãã«ç¹ç°æ§ã®æäœã¯CEA 
ã»ã°ã¡ã³ãæäœã§ãããã»ã°ã¡ã³ããšAGå ç«
éšäœã®äž¡æ¹ãå«æããCEAãã以åŸäŸ¿å®äžç¡å·
ã®CEAãšåŒã¶ã ç¡å·ã®CEAã粟補ããããã®å¥œãŸããæ¹æ³ã¯ã
äžçŽåºçºçµæç©ãAGæäœããã€ãŠåžçããåºçº
çµæç©ã®æªçµåæ®éšãé€å»ãããããŠCEAãAG
æäœããåé¢ããããšã䌎ããäžçŽçµæç©äžã«å
åšããããç¥ããªãAGããCEAãæåã«åé¢ã
ãå¿ èŠã¯ãªããAGã®AGæäœã«å¯Ÿãã芪åæ§ã¯
ç¡å·ã®CEAã®ãããããèããé«ãããã®ããã
AGæäœãžçµåããAGãéé¢ããAGæäœçµå
CEAã®æº¶é¢ã®ããã®æ¡ä»¶ã®æ³šææ·±ãéžæããã³
å¶åŸ¡ã¯ãäºã€ã®ç©è³ªã®AGæäœã«å¯Ÿãã芪ååã®
å·®ã«åºã¥ããŠCEAãAGããåé¢ããããšãå¯èœ
ã«ããã§ãããã ãã€ãŠç²Ÿå·§ãªæäœã¯ãäžçŽCEAå«æçµæç©ã
CEA ã»ã°ã¡ã³ãã ããçµåãåŸãæäœãšæ¥è§Š
ãããçµåç©è³ªãçµæç©æ®éšããåé¢ããæäœã«
ããåžçãããCEAãåé¢ããŠäžéçµæç©ãç
æãããäžéçµæç©äžã®ç¡å·ã®CEAãAGæäœãž
çµåãããçµåããç¡å·ã®CEAãæ®éšããåé¢
ãããããŠç¡å·ã®CEAãAGæäœããåé¢ããã
ãšãå«ãã çµåCEAãæããæäœãæªçµåç©è³ªã®æ®éšã
ãåé¢ããããšãå«ãåè¿°ã®ã¹ãããã¯ãæäœã
溶液ããåé¢ããããã®ä»»æã®æ¢ç¥æ¹æ³ã«ãã€ãŠ
éæããããšãã§ããããã®ãããªæ¹æ³ã¯ãæ®é
æäœãäžæº¶åããããšã䌎ããããã¯æäœã
CEAãžçµåããåããåŸã®ãããã§ãå®æœãã
ããšãã§ããã 奜ãŸããã¯ã該æäœã¯CEAãšæ¥è§Šãããåã«
æ°Žäžæº¶æ§åããããããã¯æäœãæ°Žäžæº¶æ§æ äœãž
å ±æçµåãããïŒBiou et alïŒâChin.Biochen.â
ãOttawaã10ãïŒãïŒ141âïŒã1977ãïŒããŸãã¯æ
äœãéå ±æçµåçã«é©åœãªæ äœãžåžçãã
ïŒWang et alïŒâClin.Chem.â25ãïŒãïŒ546âïŒ
ã1979ãïŒããšã«ãã€ãŠéæãåŸãã代衚çãªæ äœ
ã«ã¯æ¶æ©ããã¹ãã©ã³ã®ãããªããªãªãŒã«ãã»ã«
ããŒã¹ãã¬ã©ã¹ãŸãã¯ãã€ãã³ãå«ããæ äœã¯ç¹
ç¶ç¶å¡ãããŒãºãŸãã¯é¡ç²ã®åœ¢ã§ãããæ äœãæ
äœãžå ±æçµåã«ãã€ãŠçµåããããšããã¢ããã
ãšãŒãã«ãŸãã¯ãšã¹ãã«ã®ãããªææ©çµååºãæ
äœãæ äœãžå ±æçµåããããã«çšãããããæäœ
ãäžæº¶åããããã®é©åœãªææ³ã¯åœæ¥è ã«ãã€ãŠ
容æã«éžæããããããŠæ¬çºæã«ãšã€ãŠéèŠã§ãª
ãã AGæäœããã³CEA ã»ã°ã¡ã³ãæäœã¯åžè²©
ãããŠããããŸãã¯ãããã¯æ¢ç¥æ¹æ³ã§èª¿è£œãã
ããšãã§ãããAGæäœã¯ã¢ãžãŠãã³ãäžã®AG
溶液ã«ããå ç«åããããšã«ããããŠãµã®ãŸãã¯
ã€ã®ã®ãããªå®éšåç©äžã«å®¹æã«ã€ããããã CEA ã»ã°ã¡ã³ãæäœã¯åè¿°ã®ããã«CEAã
調補ããå®éšåç©ãå ç«åãããããŠCEAãšå
ãèµ·æºããã®æ£åžžçµç¹ã§æè¡æž ãåžçããããšã«
ãã€ãŠè£œé ãããããã®æåŸã®å·¥çšã¯äžè¬ã«æ £çš
ã§ããããããŠããã¯AGæäœãé€å»ããããã©
ãããã®ç®çãšããŠåç©ãå ç«åããããã«äœ¿çš
ããCEA補å€äžã«ååšãåŸãæ£åžžãªéCEA借é
ç©ã«å¯Ÿããæäœã®é€å»ãå«ããå ç«åããåç©ã
ãã®æè¡æž ã¯ãã®ãŸã䜿çšããŠãããããŸãã¯æ¢
ç¥ã®æ æ§ãäŸãã°ã¯ãããã°ã©ãã€ãŒãé»æ°æ³³
åãããã³ææã®é¡äŒŒæ¹æ³ã§ããã«ç²Ÿè£œããããš
ãã§ããã å žåçã«ã¯ãç¡å·ã®CEAã¯æäœãèåã·ã¢ã³
掻æ§åæ¶æ©ããã¹ãã©ã³ãžçµåããããšã«ããã
æšèããããŸãã¯å€©ç¶ããªãã¡æšèããªãCEA
補å€ããååããããäžæº¶æ§æäœã¯ã«ã©ã ã«å å¡«
ããããããŠäžæ§PHè¿ãã§ç·©è¡æ¶²ã§å¹³è¡¡åãã
ããæšèãããããŸãã¯å€©ç¶CEAã¯ã«ã©ã äžã®
éç¹ç°æ§çµåãæžããã®ãå©ãããããæ£åžžè¡æž
ãšæ··åãããã次ã«CEAçµæç©ãé垞宀枩ã§ã«
ã©ã ãžå ãããããçµæç©ãæäœãšæ¥è§Šãä¿ã€ãŠ
ããæéã¯æ°åïŒééæéïŒããçŽ24æéãŸã§å€
åããã§ããããçŽ10æéãäžè¬ã«å¥œãŸãããã€
ã³ããŠããŒã·ãšã³æéãé·ããã°é·ãçšãããå€
éã®CEAååãåŸãã§ãããããæéã¯éèŠã§
ãªãã ã€ã³ããŠãŒãã·ãšã³ãçµäºããåŸãæ®ãã®æªçµ
ååç»ã¯äžæ§è¿ãã«ä¿ã€ãç·©è¡æ¶²ã§æº¶é¢ãããã
次ã«çµåããåç»ãéé¢å€ã§æº¶é¢ããããæåâ
æäœè€åäœãåé¢ãããä»»æã®ç©è³ªãŸãã¯æ¡ä»¶ã
éé¢å€ãšããŠäœ¿çšãåŸããé žã®ã»ãã®äŸã¯ãå°¿çŽ
ããã³å¡©é¡ãå«ãã溶é¢å·¥çšã¯CEA溶é¢ãæ倧
ã«ããªãããAG溶é¢ãæå°ã«ããããã«æé©å
ãããããã®ããšã念é ã«çœ®ããåœæ¥è ã¯åºçºçµ
æç©ã®æ¬è³ªãäžæº¶æ§æäœãææã®ç²Ÿè£œåºŠãCEA
ãæšèåãããŠãããã©ããããããããªãæšè
ã®æ¬è³ªã«äŸåããŠæº¶é¢æ¡ä»¶ã調ç¯ããé©åœãªæº¶é¢
液ãéžæããã§ãããã ååãããç¡å·ã®ãæšèãŸãã¯å€©ç¶CEAã¯ã
ããæããªãã°æ®ãã®AGãé€å»ããããããã«
粟補ãããããŠäœ¿çšãããŸã§åçµä¹Ÿç¥ãããã¯å·
åä¿åããããšãã§ããã粟補ããç¡å·ã®CEA
ã¯ãããŸã§CEAã«é©ããã©ããªçšéã«ããäŸã
ã°æ¢ç¥ã®CEAã¢ãã»ã€ã«ãããŠãã¬ãŒãµãŒïŒæš
èããé¡çžäœïŒãšããŠããŸãã¯CEAæäœè£œé ã®
ããã®å ç«æºãšããŠäŸããããšãã§ãããäžèšã®
ããã«èª¿è£œãã粟補CEAãã¬ãŒãµãŒã®äœ¿çšã¯ã
æ¢ç¥ã¢ãã»ã€ã§å®è¡ãããŠãããããªè©Šæã®éå¡©
çŽ é žãããã¯ç±æœåºãçç¥ã§ãããããŠè¡æž ã®ã
ããªæªåŠçè©ŠæãçŽæ¥äœ¿çšã§ããã®ã§ãã€ã ãã¢
ãã»ã€ã®æ床ãå¢ãã ã€ã ãã¢ãã»ã€ äžã§èª¿è£œããã粟補ããæšèããCEAãå žå
çãªç«¶ååã€ã ãã¢ãã»ã€ã«äœ¿çšããããšã¯æ¬çº
æã®ç¯å²å ã§ããããã®ããšã¯ãæšèããCEA
ãšãã¹ãè©Šæãšãéãããæ°ã®CEAæäœçµåéš
äœã«å¯ŸããŠç«¶åãããã®åŸæäœçµåç©è³ªãæšèã«
ã€ããŠå®éããããããå€éã®è©ŠæCEAãååš
ããã°ããã®ãšãã¯æšèããCEAã®å€§éšåã¯ç«¶
åçã«æäœãã眮æããããè©Šæäžã®CEAãäœ
ããã°ãã®å察ã§ãããAGæäœã«ãã€ãŠçµåã
ããªãã¿ã³ãã¯è³ªãå®è³ªäžå«ãŸãªãæšèãã
CEAãããªãã¡ããã®ããã«çµåãããªãã¿ã³
ãã¯è³ªãçŽ40ïŒ ä»¥äžããå«ãŸãªãæšèããCEA
ã«ããããããã³ãã©ããã·ãŠããã³CISãã販
売ãããŠããåžè²©ã®ã©ãžãªã€ã ãã¢ãã»ã€ã«ããª
ãã®æ¹åãåŸãããšãã§ããã粟補ããæšè
CEAã¯æªç²Ÿè£œãã¬ãŒãµãŒãããCEAæäœã«å¯Ÿã
ãŠèããå ç«åå¿æ§ã§ãããåé¡ã¯ããããŸã§
CEAã¯å€§éšååäžã§ãããšèããããŠãããã
å®éã«ã¯ç¡å·ã®CEAäžã«AGããã³ïŒ°ã»ã°ã¡ã³ã
決å®éšåãååšãããã¹ãè©ŠæCEAã®æªç¥å²å
ã ããã»ã°ã¡ã³ã決å®éšåã§ãããšããããšã§
ãããè©Šæã»ã°ã¡ã³ãã¯åŸæ¥ã®ç«¶ååã€ã ãã¢
ãã»ã€ã«ãããŠæšèããã³è©Šæã®ç¡å·ã®CEAãš
競åããããã«ããç¡å·ã®CEAã®å®éã劚害ã
ããã®ãšæšæž¬ãããããã®æœåšçãªåŠšå®³ã¯ããã®
ç¹ãèæ ®ã«å ¥ããã¢ãã»ã€ãããã³ãŒã«ãéžã¶ã
ãšã«ãã€ãŠæé€ããããåŸã€ãŠãæ¬çºæã®æ¹è¯ã¯
ç¡å·ã®CEAã®ã¿ãããªãã¡AGããã³ïŒ°ã»ã°ã¡ã³
ãã«å ±éãªå ç«åŠçã«è¡šããã決å®å åãå«æã
ãç©è³ªã®ã¿ã枬å®ããããšãå«ããããã¯éAG
æäœäº€å·®åå¿æ§ç©è³ªããã¹ãè©Šæããäºå粟補ã«
ãã€ãŠé€å»ãã次ã«è©Šæã競åç³»ã«ãã€ãŠå®éã
ãããšã«ãã€ãŠéæããããšãã§ãããããããª
ããã奜é©ãªå®éæ³ã¯æ¬çºæã«ãã€ãŠã¯æ¹è¯ãã
ãµã³ãã€ããæ³ã§ããã ãµã³ãã€ããã€ã ãã¢ãã»ã€æ³ã¯ããç¥ãããŠ
ãããäžè¬çã«ããã®ã¢ãã»ã€ã«äœ¿çšãããè©Šè¬
ã¯è¢«åæç©è³ªã«å¯Ÿããäžæº¶æ§æäœãšã被åæç©è³ª
ã«å¯Ÿããæšèããå¯æº¶æ§æäœãšã§ãããäºæãã
ãè©Šæ被åæç©è³ªéå£ãããå°æ°ã®è¢«åæç©è³ªçµ
åéšäœãå«æããéã®äžæº¶æ§æäœã䜿çšãããã
ãã®ã¢ãã»ã€ã¯äžè¬ã«äžæº¶æ§æäœããã¹ãè©Šæã
次ã«æšèããæäœãšé çªã«æ¥è§Šãããçµåããæš
èãã¢ãã»ã€ããããšã«ãã€ãŠå®æœãããã被å
æç©è³ªã¯äžæº¶æ§æäœãšæšèæäœãšã®éã«ãµã³ãã€
ããããããããã«ã¯å¿è«è¢«åæç©è³ªãå°ãªããš
ãäºã€ã®å ç«çµåéšäœãæã€ãŠããããšãèŠã
ããç¡å·ã®CEAã®ã¢ãã»ã€äžã®CEA ã»ã°ã¡ã³
ãã®ååšã®å¯èœæ§ã¯ãã®ã¢ãã»ã€ã®äžã€ã®å€æ³ã
奜ãŸãããã®ãšãããå¯æº¶æ§ã®æšèããæäœãšäž
溶æ§æäœãšã¯ãå ±ã«åã被åæç©è³ªãšçµåããã
ãã©ãåãæäœã§ã¯ãªããããªãã¡äžæ¹ã®æäœã¯
ç¡å·ã®CEAã®ïŒ°ã»ã°ã¡ã³ã決å®å åã«åãã第
äºã®æäœã¯CEA AG決å®å åãçµåããããšã
ã§ãããããã¯AGãŸãã¯ïŒ°ã»ã°ã¡ã³ãã®ã©ã¡ã
ããç¡å·ã®CEAã®æš¡å£ãããããšãé²æ¢ããã ãã®æ¹è¯ãããµã³ãã€ããæ³ã¯ã (a) ãã¹ãè©ŠæãCEAã®ïŒ°ã»ã°ã¡ã³ãã«å¯Ÿãã
æ°Žäžæº¶æ§æäœãå«ããã¹ããããªãã¯ã¹ãšæ¥è§Š
ãããããšã (b) ãã¹ãè©Šæã®æ®ããé€å»ããããšã (c) ãã¹ããããªãã¯ã¹ãAGã«å¯Ÿããæšèãã
æäœãšæ¥è§Šãããããšã (d) çµåããªãæšèããæäœãé€å»ããããšã (e) çµåãŸãã¯æªçµåæšèã®éã枬å®ããããš ãå«ãã äŸç€ºã®ããããã®æ¹æ³ã®æçµçæç©ã¯ä»¥äžã®ã
ãã«ãªãã§ãããã ãè¡šã äžèšã«ãããŠç¹ç·ã¯å ç«çµåã§ãããâ»ã¯æšè
ã§ããã çµåããCEA ã»ã°ã¡ã³ãã¯æšèããæäœã«
ãã€ãŠçµåããããåŸã€ãŠCEAãšããŠå®éãã
ãªããååšããããšãããCEA ã»ã°ã¡ã³ãã¯
AGæäœãçµåããªããïŒãŸãã¯ãã以äžã®å¥ã
ã®å ç«éšäœãçµåããããšãã§ããåçš®ã®æäœã
䜿çšããããšãã§ãããå¿è«ïŒ°ã»ã°ã¡ã³ãæäœã¯
AGãšäº€å·®åå¿æ§ã§ãã€ãŠã¯ãªããããŸãAGæ
äœã¯CEA ã»ã°ã¡ã³ããçµåããŠã¯ãªããªãã
ããã«ãããããããæäœã¯ããããã§ããã ã
åäžã§ããããšãæãŸãããããªãã¡æ¢ç¥ææ³ã§
ãã€ããªããŒãå¹é€ã«ãã€ãŠåŸãããšãã§ããã
ããªãåäžã®å ç«éšäœã«åããããåäžã®æäœã
䜿çšãã¹ãã§ããã ã»ã°ã¡ã³ãæäœã¯ãAGæäœãå ã«è£œé ãã
ãæ¹æ³ãšåãæ¹æ³ã§äžæº¶æ§åããããšãã§ããã
奜ãŸããã¯ãæäœã¯ãããããªã¹ãã¬ã³ããŒãºãŸ
ãã¯ããªãããã¬ã³è©Šéšç®¡å åºãžåžçãããããš
ã«ãã€ãŠäžæº¶æ§åãããã æšèããæAGæäœã¯æ°èŠã§ãããšæãããã
åè¿°ã®CEAã«å¯Ÿããæšèã®ã©ãããAGæäœã«ã
䜿çšã§ããä»ã®æšèããæäœãšåãæ¹æ³ã§è£œé ã
ãããäŸãã°ãæŸå°æšèããæCEAæäœã®è£œé
æ³ãèšèŒããç±³åœç¹èš±ç¬¬3927193å·åç §ã奜ãŸã
ãæšèã¯é µçŽ ããã³ã©ãžãªã¢ã€ãœããŒãã§ããã
æã奜ãŸããã®ã¯æŸå°æ§ãšãŒãã§ãããæŸå°æ§ãš
ãŒãåã®ããã®å¥œãŸããæ¹æ³ã¯ãDermody et
al.ïŒâClinical Chemistryâ25(6)ïŒ989â995
ïŒ1979ïŒãŸãã¯Parsons et al.ïŒâAnalytical
Biochemistryâ95ïŒ568â574ïŒ1979ïŒã«èšèŒãã
ãŠããããã«ã¯ãã©ãã³âãŸãã¯ã©ã¯ããã«ãª
ãã·ããŒãŒãïŒ 125IïŒãšãŒãããããã·ããšãã«
ããããªããŒãââããããã·ã¹ã¯ã·ãã¡ãŒã
ãšã¹ãã«ïŒBolton et al.ïŒâBiochem.Journalâ
133ïŒ529â533ã1973ãïŒãïŒ 125IïŒãžãšãŒããã«ãª
ã¬ã»ã€ã³ã€ãœããªã·ã¢ããŒãïŒGabel et al.ïŒ
âAnalytical Biochemistryâ86ïŒ396â406
ã1973ãïŒãïœâãããã·ã«ã«ããã«ââïŒ125IïŒ
ãšãŒãããã·ã³ââããããã·ã¹ã¯ã·ããããš
ã¹ãã«ïŒAssoian et al.ïŒâAnalytical
Biochemistryâ103ïŒ70â76ã1980ãïŒããŸãã¯IC1
ïŒMontelaro et al.ïŒâAnalytical
Biochemistryâ99ïŒ92â96ã1979ãïŒã®ãããªå€
éšæŸå°æ§ãšãŒãåå°ååã䜿çšãããã¯ãã©ãã³
æ³ã奜ãŸããå ·äœäŸã§ããã æ¬çºæã¯ä»¥äžã®å®æœäŸã«ããã«è©³ããèšèŒãã
ãã å®æœäŸ ïŒïŒåèäŸïŒ AGæäœïŒããã¹ããŸãã¯ãã€ã«ã¹ïŒããã®æ
å³ããå®æœäŸããã³Greenwood et al.ïŒ
âBiochem.J.â89ïŒ114â123ïŒ1963ïŒã®æ¹æ³ã«ã
ã€ãŠ 125Iã§æšèãããæäœã®50ÎŒïœéšåæšæ¬ã
Greenwoodãã®æ¹æ³ã§åŠçããã»ãã¢ããã¯ã¹
â50ã®ã«ã©ã ãééãããããšã«ãã€ãŠéé¢ãš
ãŒããåé¢ãããæšèããæäœåç»ã¯ãïŒïŒ åãŠ
ã·è¡æž ããã³æèå€ãšããŠ0.1ïŒ NaN3ãå«ãåžé
液äžã«çŽ3ÎŒCiïŒmlã«åžéãããã補åã¯ïŒâã§
貯èµããã å®æœäŸ ïŒ ãã®æ¹æ³ã¯ç¡å·ã®CEAã枬å®ããããã®äŒå³
ãããæ¹è¯ãµã³ãã€ããã€ã ãã¢ãã»ã€ãèšèŒã
ãã CEAã¯çµè žã®äžæ¬¡ã¢ããã«ã«ãããŒãã®è転
移ããã該çµç¹ã®Warringãã¬ã³ããŒäžçéã®èž
çæ°Žäžã«ãã¢ãžãã€ãºããããšã«ãã€ãŠç²Ÿè£œãã
ãããã¢ãžããŒãã¯8000rpmã«ãããŠ30åéïŒâ
ã§é å¿ããããšã«ããæž æŸåããããäžæž ã1M
éå¡©çŽ é žãšæ··åããæ²æ®¿ãé å¿ã«ãã€ãŠé€å»ã
ããäžæž ãèžçæ°Žã§ïŒæ¥ééæããã ã¿ã³ãã¯è³ª50mgïŒmlãå«ãã§ããéå¡©çŽ é žæœåº
åç»ãPH7.8ã®0.05Mãªã³é žç·©è¡æ¶²ã§å¹³è¡¡åãã
ã»ãã¢ããã¯ã¹ïŒ§â200ã«ã©ã ïŒ170Ã1.5cmïŒã§
ã²ã«ãéããããšã«ãã€ãŠç²Ÿè£œããã溶åºæ¶²ãïŒ
mlã¥ã€ã®éšåæšæ¬ãšããŠéããã¿ã³ãã¯è³ªã
280nmã«ãããŠããããŠCEAãã©ãžãªã€ã ãã¢
ãã»ã€ã§ã¢ãã¿ãŒããã溶åºæ¶²ã®æåã®ã¿ã³ãã¯
質ããŒã¯ïŒç©ºéäœç©ïŒãéããŠæ¿çž®ãã次ã«ã²ã«
ãéãããè¿ããã CEA ã»ã°ã¡ã³ãæäœã¯ãäžèšCEA補å€ã®ïŒ
mgãå®å šãªããã€ã³ãã¢ãžãŠãã³ãäžã«ä¹³åãã
ãšãã«ãžãšã³ããŠãµã®ã«æ³šå°ããCEAã¿ã€ã¿ãŒ
ãäžæããåŸã«è¡æž 20mlãæ¡åãããããŠæè¡æž
ãéããèèçµç¹ããã³æ£åžžããè¡æž ãžåžçãã
ãããšã«ãã€ãŠäœãããã補å€ã¯ïŒâã§è²¯èµã
ãã çŽïŒmlã®CEA ã»ã°ã¡ã³ãæè¡æž ãç±³åœç¹èš±
第3686346å·ã«ãã€ãŠããªãããã¬ã³è©Šè¬ç®¡ã®å
è¡šé¢ã®åºã«å¡åžãããè žã®ã¢ããã«ã«ãããŒãã
æããããšãæ¢ç¥ã®æ£è ã®è¡æž è©Šæ0.1mlãšãæ£
åžžã³ã³ãããŒã«0.1mlãšãïŒç³»åå¡åžè©Šéšç®¡äžã«
ãããããã12æéã€ã³ããŠããŒããããçµåã
ãªãè©Šæãæ°Žã§åè©Šéšç®¡ããæŽæµããå®æœäŸïŒã«
ãããŠèª¿è£œããæšèããAGæäœ0.3mlãåè©Šéšç®¡
ãžå ãã24æéã€ã³ããŠããŒãããçµåããªãæš
èæäœãæ°Žã§è©Šéšç®¡ããæŽæµãããããŠè©Šéšç®¡ãž
çµåããæŸå°èœã枬å®ãããè©Šæè©Šéšç®¡ãžçµåã
ãæŸå°èœã¯ã³ã³ãããŒã«äžã®ãããããèãã倧
ã§ãã€ãã å®æœäŸ ïŒïŒåèäŸïŒ ãã®å®æœäŸã¯æŸå°æ§ãšãŒãåCEA補å€ïŒãã
ãã³ãã©ããã·ãŠãïŒ1000000cpmïŒã®ç²Ÿè£œæ³ãèš
èŒãããAGã«å¯Ÿããäžæº¶æ§æäœã¯AGæäœïŒã¬
ã³ãã°ãããªã³âDakoïŒ300mgãèåã·ã¢ã³æŽ»æ§
åã»ãã¢ããŒãº4BïŒãã¢ã«ãã·ã¢ïŒ30mlãžçµåã
ãããšã«ãã€ãŠäœããããäžæº¶æ§æäœã¯ïŒÃ1.0
cmã®ã«ã©ã ã«å å¡«ãããã 125IæšèCEAã®éšå
æšæ¬ãæ£åžžãŠãµã®è¡æž ãšæ··åããåèšã«ã©ã ãžæ³š
ããPH7.8ã®0.05Mãªã³é žç·©è¡æ¶²ã§æº¶é¢ããïŒçª
ç®ã®éšåæšæ¬ã泚å ããçŽåŸïŒâã§äžå€ã€ã³ããŠ
ããŒãããæ£åžžãŠãµã®è¡æž 0.1mlãã«ã©ã ã«æ³šå
ãããããŠã«ã©ã ããªã³é žç·©è¡æ¶²ã§æº¶é¢ãããã
ããã®åç»ãæªçµååç»ãšåŒã¶ãçµååç»ã¯æªçµ
ååç»ãéããåŸãäž¡æ¹ã®å ŽåãšãPH2.2ã®0.1M
ã°ãªã·ã³ç·©è¡æŽã§æº¶é¢ãããååç»ã®æŸå°èœãã«
ãŠã³ããããè¡šïŒã¯ãã®çµæãèšé²ããã ãè¡šã ãã¬ãŒãµãŒã®å°éãã«ã©ã ã«æ®ãã®ã§ãçµåã
ãã³æªçµåæŸå°çã¯å šäœã§100ïŒ ã«éããªããå
æ§ãªçµæã¯ä»ã®ïŒäŸçµŠæºïŒããã¹ãããã³ãã€ã«
ã¹ã©ãã©ããªãŒãºïŒããã®AGæäœã䜿çšããæŸ
å°æ§ãšãŒãåCEAã®ããªãšãã¬ã³ã°ãªã³ãŒã«ä¿
é²æ²æ®¿æ³ã«ãã€ãŠåŸããããæ®ãã©ãã¹ãŠã®çµå
溶é¢æŸå°èœã¯AGæäœïŒDakoïŒã§ããCEAæäœ
ã§ãæ²æ®¿ãããããããæªçµååç»äžã«ã¯ã³ã³ã
ããŒã«ã«æ¯èŒããŠææãªæ²æ®¿æŸå°èœã¯çºèŠãããª
ãã€ããAGæäœãçµåããCEAã¯ã(1)AGã¯AG
æäœããã®CEAæŸå°èœãçšéåå¿çã«çœ®æãã
(2)ä»ã®è¡æž ã¿ã³ãã¯è³ªã«å¯Ÿããæè¡æž ã¯CEAã
æ²æ®¿ããªãããšããå ç«ç¹ç°æ§ã§ããããšã瀺ã
ããã çµåãã溶é¢åç»ã¯ãåžè²©CEA枬å®ããã
ïŒCISããã³ãããã³ãã©ããã·ãŠïŒã®æªç²Ÿè£œã
ã¬ãŒãµãŒã«ä»£ããŠçšããããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ (a) ãã¹ãè©ŠæãCEAã®ïŒ°ã»ã°ã¡ã³ãã«å¯Ÿ
ããæ°Žäžæº¶æ§æäœãå«ããã¹ããããªãã¯ã¹ãš
æ¥è§Šãããããšãšã (b) ãã¹ãè©Šææ®éšãé€å»ããããšãšã (c) ãã¹ããããªãã¯ã¹ãæšèããAGã«å¯Ÿãã
æäœãšæ¥è§Šãããããšãšã (d) æªçµåã®æšèããæäœãé€å»ããããšãšã (e) çµåããããŸãã¯çµåããªãæšèã枬å®ãã
ããšãããªããã¹ãè©Šæäžã®CEAã®å®éæ¹æ³ã ïŒ ãã¹ãè©Šææ®éšããã³æªçµåæšèæäœã¯æŽæµ
ã«ãã€ãŠãã¹ããããªãã¯ã¹ããé€å»ãããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé ã®æ¹æ³ã ïŒ ãã¹ãè©Šæã¯CEA ã»ã°ã¡ã³ãæäœãšã®æ¥
觊以åã«å ç±ããŸãã¯ç³ã¿ã³ãã¯è³ªæº¶åªã§æœåºã
ããªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®æ¹æ³ã ïŒ ãã¹ããããªãã¯ã¹ã¯CEAã®ïŒ°ã»ã°ã¡ã³ã
ã«å¯Ÿããæ°Žäžæº¶æ§æäœãå«ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é ã®æ¹æ³ã ïŒ æšèã¯ã©ãžãªã¢ã€ãœããŒããŸãã¯é µçŽ ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®æ¹æ³ã ïŒ ãã¹ããããªãã¯ã¹ã¯ããªãªã¬ãã€ã³è©Šéšç®¡
ã§ãããåèšæäœã¯è©²è©Šéšç®¡ã®å è¡šé¢ãžã®åžçã«
ãã€ãŠæ°Žäžæº¶æ§ã«ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã®
æ¹æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/269,217 US4489167A (en) | 1981-06-02 | 1981-06-02 | Methods and compositions for cancer detection |
| US269217 | 1981-06-02 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2040884A Division JPH02238000A (ja) | 1981-06-02 | 1990-02-20 | ããèå æ§æåã®ç²Ÿè£œæ³ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58758A JPS58758A (ja) | 1983-01-05 |
| JPH0244030B2 true JPH0244030B2 (ja) | 1990-10-02 |
Family
ID=23026305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57095572A Granted JPS58758A (ja) | 1981-06-02 | 1982-06-02 | ããèå æ§æåã®å®éæ¹æ³ |
| JP2040884A Granted JPH02238000A (ja) | 1981-06-02 | 1990-02-20 | ããèå æ§æåã®ç²Ÿè£œæ³ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2040884A Granted JPH02238000A (ja) | 1981-06-02 | 1990-02-20 | ããèå æ§æåã®ç²Ÿè£œæ³ |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4489167A (ja) |
| JP (2) | JPS58758A (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962187A (en) * | 1984-11-28 | 1990-10-09 | Cota Biotech | Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same |
| GB8618443D0 (en) * | 1986-07-29 | 1986-09-03 | Univ London | Monoclonal antibodies |
| US6022958A (en) * | 1986-08-13 | 2000-02-08 | Bayer Corporation | cDNAs coding for members of the carcinoembryonic antigen family |
| US5231009A (en) | 1986-08-13 | 1993-07-27 | Molecular Diagnostics, Inc. | Cdnas coding for members of the carcinoembryonic antigen family |
| US5122599A (en) * | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
| US4914021A (en) * | 1988-03-04 | 1990-04-03 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
| US5204450A (en) * | 1988-03-04 | 1993-04-20 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
| US5241052A (en) * | 1988-03-04 | 1993-08-31 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
| US4921789A (en) * | 1988-04-20 | 1990-05-01 | New England Deaconess Hospital Corporation | Marker for colorectal carcinoma and methods of detecting the same |
| US5179008A (en) * | 1989-02-09 | 1993-01-12 | Wisconsin Alumni Research Foundation | Hybridoma and monoclonal antibody to FHAP |
| US5001052A (en) * | 1989-02-09 | 1991-03-19 | Wisconsin Alumni Research Foundation | Immunoassay for FHAP and antibody useful therewith |
| US5274081A (en) * | 1989-09-20 | 1993-12-28 | Immuno A.G. | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
| US5576175A (en) * | 1989-09-20 | 1996-11-19 | Immuno Aktiengesellschaft | Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen |
| US5200316A (en) * | 1990-02-15 | 1993-04-06 | Miles Inc. | Immunoassay methods using noncross reactive cea gene family members antibodies |
| US5278290A (en) * | 1991-05-31 | 1994-01-11 | Applied Biotechnology, Inc. | Binding protein for CEA and uses thereof |
| US5245017A (en) * | 1991-05-31 | 1993-09-14 | Applied Biotechnology, Inc. | Method for isolating CEA-binding protein |
| US5281697A (en) * | 1991-05-31 | 1994-01-25 | Applied Biotechnology, Inc. | CEA-binding protein and uses thereof |
| JPH07508352A (ja) * | 1993-04-22 | 1995-09-14 | ãã€ããã€ã³ã¿ãŒãã·ã§ãã«ãã€ã³ã³ãŒãã¬ã€ããã | è «çããŒã«ãŒå¯Ÿç § |
| US5747268A (en) * | 1993-04-22 | 1998-05-05 | Dade International Inc. | Tumor marker control |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4180499A (en) * | 1971-01-27 | 1979-12-25 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
| US3960827A (en) * | 1972-07-10 | 1976-06-01 | Bjoerklund K B | Cancer associated polypeptide antigen, process for its preparation, process for preparing antibodies, process of cancer diagnosis and composition useful as an immunizing agent |
| US4132769A (en) * | 1974-10-30 | 1979-01-02 | Osther Kurt B | Cancer antigen, cancer therapy, and cancer diagnosis |
| US4140753A (en) * | 1976-04-30 | 1979-02-20 | Scripps Clinic & Research Foundation | Diagnostic method and reagent |
| SE7609263L (sv) * | 1976-08-20 | 1978-02-21 | Wadsworth Charlies | Forfaringssett for faststellande av kvantiteten av viss i en biologisk vetska loslig komponent, samt apparat for utovande av forfarandet |
| US4075194A (en) * | 1976-12-09 | 1978-02-21 | Yeda Research And Development Co., Ltd. | Novel synthetic undecapeptide and clinical assay |
| US4178285A (en) * | 1978-12-20 | 1979-12-11 | Felts James M | Separation of active α1 -acid glycoprotein and utilization in the lipoprotein lipase enzyme system |
-
1981
- 1981-06-02 US US06/269,217 patent/US4489167A/en not_active Expired - Lifetime
-
1982
- 1982-06-02 JP JP57095572A patent/JPS58758A/ja active Granted
-
1990
- 1990-02-20 JP JP2040884A patent/JPH02238000A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4489167A (en) | 1984-12-18 |
| JPH02238000A (ja) | 1990-09-20 |
| JPS58758A (ja) | 1983-01-05 |
| JPH0428718B2 (ja) | 1992-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4312853A (en) | Radioimmunological determination of procollagen (type III) and procollagen peptide (type III) | |
| JPH0244030B2 (ja) | ||
| US4737453A (en) | Sandwich immunoassay utilizing a separation specific binding substance | |
| US4353982A (en) | Immunochemical assay for creatine kinase-MB isoenzyme | |
| CA1225590A (en) | Use of anti-idiotype antibodies in immunoassays | |
| CA1181685A (en) | Method for the identification and purification of human lung tumor-associated antigens (hltaa) and clinical detection and determination of these antigens | |
| AU619827B2 (en) | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses | |
| WO1983004312A1 (en) | Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays | |
| US4264571A (en) | Radioimmunoassay of thymosin α1 | |
| JPH0467914B2 (ja) | ||
| Mercham et al. | [42] Antibodies to insoluble and solubilized elastin | |
| CA1265048A (en) | Protein which is characteristic of rheumatoid arthritis | |
| US4124700A (en) | Immunoassay for thymopoietin | |
| US4299814A (en) | Radioimmunoassay of MIF | |
| Harboe et al. | Individual antigenic specificity of human macroglobulins: Localization of antigenic determinants and their use to demonstrate formation of hybrid molecules after reduction and reassociation | |
| US4962187A (en) | Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same | |
| US5310656A (en) | Vitamin B12 assay | |
| EP0245052A2 (en) | Detection of inflammation and novel antibodies therefor | |
| Nishida et al. | Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer. | |
| US4792528A (en) | Methods for obtaining monoclonal antibodies useful in enhanced sensitivity immunoassays | |
| US4591572A (en) | Pigmentation associated, differentiation antigen of human melanoma and autologous antibody | |
| EP0166583A2 (en) | Compositions for enzyme immunoassay of prostaglandins | |
| Morgan Jr et al. | Human melanoma associated antigens: A solid-phase assay for detection of specific antibody | |
| EP0109078B1 (en) | Immunochemical assay of human chorionic gonadotropin and reagent therefor | |
| US4096237A (en) | Immunoassay for β-endorphin |